So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...

Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely the hottest medical sector story in 2024. With its offering of tirzepatide ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

A woman's hands star in a Lilly spot, shown playing key role in activities like gardening -- and discovering a lump in her ...

Read a preview of Eli Lilly below and check back for more analysis soon. Investors already know what to expect when Eli Lilly ...

Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...